Our new preprint is out!

A new preprint on how LRRK2 deregulates the most vulnerable dopamine neuron subtypes in Parkinson's disease. I am incredible thrilled about this work, as it reflects the seamless collaboration among various labs, each bringing their unique expertise—just as science should advance.

https://www.biorxiv.org/content/10.1101/2025.08.28.672006v1.full.pdf

Loukia is presenting a seminar at the Biomedical Sciences Research Center in the northern suburbs of Athens. The center's advantageous proximity to the sea adds a beautiful backdrop.

PROUD PI moment

Chris Nasios, our research technician, is officially a medical student at Duke University School of Medicine. Way to go Chris!!

LRRK2 in vulnerable dopamine neuron subtypes

Our collaborative paper with our ASAP team is now published in eLife.

https://pubmed.ncbi.nlm.nih.gov/40353820/

The Feinberg School of Medicine News Center has just featured our latest paper!!

https://news.feinberg.northwestern.edu/2025/04/30/identifying-new-therapeutic-strategies-for-psychiatric-disorders/

Our new work was featured in MDLinx. Super honored!

https://www.mdlinx.com/news/mechanism-behind-parkinsons-like-side-effects-of-antipsychotic-drugs-revealed/41ioCJpHul72UYbKgyLlF0

Another publication from the lab!

"Could LRRK2 Inhibition Be the Key to Reducing Antipsychotic Side Effects?"

Check our new publication in Molecular Psychiatry! https://www.nature.com/articles/s41380-025-03030-z

It attracted significant attention from the media.

Loukia is giving a talk in the ASAP meeting in Arizona

Collaboration, open science to find the cure for Parkinson’s disease

LRRK2 and Greek island; my two favorite things in life!

Loukia is presenting unpublished data from the laboratory at the Biennial International LRRK2 meeting in Crete, Greece

Loukia is giving a talk in Paris! Beautiful city, amazing science !